Rep. Dingell on GPIA recommendations
Executive Summary
The Michigan Democrat called "predictably and critically flawed" the recommendations for correcting the generic drug industry by an independent "blue ribbon" committee established by the Generic Pharmaceutical Industry Association. Although the advisory committee developed several "positive" recommendations, Dingell was not satisfied with the panel's proposals for dealing with scofflaw companies.